lead HMOs have been approved for use in foods in Europe and the US. We also
have a rich pipeline of other HMOs in early stages of development.
early 2016 EFSA has confirmed the safety of Glycom’s
leading ingredients 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose
in infant and follow-on formulas, processed cereal-based food and baby foods
for infants and young children and a range of other food applications. The
positive EFSA opinions were followed by the marketing approvals as is provided
by the European Commission through publication of the Implementing Decisions
which lay down the uses, use levels and specifications of the Novel
These ingredients where initially
produced by chemical synthesis but the Irish Food Safety Authority (FSAI) has
recently confirmed that the identical high purity ingredients are substantially
equivalent when produced via cell fermentation.
EFSA opinions confirming safety see:
Commission Implementing Decisions authorizing the marketing see:
For Substantial Equivalence Opinions:
LNnT Entry 359 of Commission List of Novel Food Notifications
2’-FL Entry 339 of Commission List of Novel Food Notifications
Danish HMO company invests
more than 500m DKK in Jutland production facility
order to supply the vibrant HMO market in coming years, Danish biotech company
Glycom is investing more than 500 million DKK in the acquisition and adaptation
of the Vitalys manufacturing facility in Esbjerg, Denmark. Existing Vitalys staff
will be retained and total employment at the plant will more than double in the
next 2 years as the facility is made ready for HMO production. The investment has been funded by major Danish
financial institutions and the existing shareholders.
to John Theroux, CEO of Glycom, the acquisition will create a basis for
significant international growth:
believe that HMOs represent a big opportunity to contribute to the health and
well being of millions of people around the world and to create a high quality
and substantial size Danish company in the process. We are already working with
a high quality contract manufacturing partner, and the acquisition of Vitalys
brings a second supply source and additional capacity that will insure high
volume and low cost supply for our customers.”
are small fibers which are found in human milk. They create and maintain a
strong gut barrier defence and healthy intestinal microbiotia in both infants
and adults, and they are the biggest difference between infant formula and
mother’s milk. As a result, HMOs have the
potential to address a number of global health challenges. ”HMOs are unique, wonderful, gentle, natural
compounds that offer many health benefits.
We can now manufacture them in large quantities and offer them to the
world for the first time. We are
delighted to welcome the Vitalys employees to our adventure.” says John Theroux.
is a private Danish company that was founded in 2005. It employs an international staff of
technical specialists from 15 countries from its base at DTU in Lyngby. Glycom was voted Entrepreneurial Start Up
Company of the Year in Denmark in 2010.
”Although we have a very international staff of scientific and technical
specialists and our products will be sold all over the world, we are a Danish
company with Danish research infrastructure in our labs and offices in Lyngby
and now with Danish manufacturing infrastructure in Esbjerg. I hope and intend that Glycom will become a
great example of high quality international innovation from a world class
Danish company.” says Kim Bøttkjaer, Chairman.
For further information, contact:
Glycom Chairman: Kim Bøttkjær, +45 40 45 52 13
John Theroux, +45 21 74 73 65 or email@example.com